ISIS-STAT3Rx is designed to treat cancer by inhibiting the production of a gene critical for tumor cell growth and survival. Signal transducer and activator of transcription 3 (STAT3) is over-active in a variety of cancers, including brain, lung, breast, bone, liver and multiple myeloma and promotes tumor cell growth and prevents cell death. In preclinical studies, ISIS-STAT3Rx demonstrated antitumor activity in animal models of human cancer with an attractive safety profile. ISIS-STAT3Rx will be evaluated in a variety of cancers where STAT3 is believed to play a key role such as liver cancers and multiple myeloma.
"Cancer is a therapeutic area in which we believe antisense drugs could have a profound treatment impact. STAT3 is a target that is widely viewed as promising, but it is inaccessible to traditional drug approaches due to the nature of the protein and its function in the cell," said Brett P. Monia, Ph.D., Vice President, Drug Discovery and Corporate Development. "ISIS-STAT3Rx adds to our already broad and mature cancer franchise consisting of a Phase 3 drug and three Phase 2 drugs, each with promising clinical data. These drugs inhibit many of the processes that tumor cells use to grow, proliferate, and metastasize."
At 12:00 p.m. Eastern Standard Time today, January 6, Isis will conduct a live webcast conference call to discuss the new development candidates added to its pipeline and related activities. Interested parties may listen to the call by dialing 800-295-4740 and refer to passcode "ISIS2011", or access the webcast at www.isispharm.com. A webcast replay will be a
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved